{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:23:37Z","timestamp":1786987417517,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.contraception.2021.03.031","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T12:17:10Z","timestamp":1617625030000},"page":"8-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Abortion exceptionalism and the mifepristone REMS"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6406-7429","authenticated-orcid":false,"given":"Jaclyn J.","family":"Serpico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2021.03.031_bib0001","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2105\/AJPH.2017.304278","article-title":"State law approaches to facility regulation of abortion and other office interventions","volume":"108","author":"Jones","year":"2018","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.contraception.2021.03.031_bib0002","first-page":"6","article-title":"Abortion and informed consent: how biased counseling laws mandate violations of medical ethics","volume":"19","author":"Vandewalker","year":"2012","journal-title":"Mich J Gend Law"},{"key":"10.1016\/j.contraception.2021.03.031_bib0003","first-page":"1047","article-title":"Abortion exceptionalism and undue burden preemption","volume":"71","author":"Borgmann","year":"2014","journal-title":"Wash Lee Law Rev"},{"key":"10.1016\/j.contraception.2021.03.031_bib0004","first-page":"1175","article-title":"Abortion distortions","volume":"71","author":"Corbin","year":"2014","journal-title":"Wash Lee Law Rev"},{"key":"10.1016\/j.contraception.2021.03.031_bib0005","first-page":"99","article-title":"Essentially elective: the law and ideology of restricting abortion during the COVID-19 pandemic","volume":"106","author":"Jessie Hill","year":"2020","journal-title":"Va Law Rev"},{"key":"10.1016\/j.contraception.2021.03.031_bib0006","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1056\/NEJMe1604462","article-title":"A new label for mifepristone","volume":"374","author":"Greene","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2021.03.031_bib0007","unstructured":"United States Government Accountability Office, Report to Congressional Requesters No. GAO-08-751: Approval and Oversight of the Drug Mifeprex. 2008. https:\/\/www.gao.gov\/products\/gao-08-751."},{"key":"10.1016\/j.contraception.2021.03.031_bib0008","unstructured":"Risk evaluation and mitigation strategies. 21 U.S.C. \u00a7355-1 (2020)."},{"key":"10.1016\/j.contraception.2021.03.031_bib0009","volume":"110-85","author":"Food and Drug Administration","year":"2007"},{"key":"10.1016\/j.contraception.2021.03.031_bib0010","unstructured":"Drugs@FDA FDA. FDA-Approved Drugs. Abbreviated New Drug Appl ((ANDA):):091178. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=091178."},{"key":"10.1016\/j.contraception.2021.03.031_bib0011","author":"Center for Drug Evaluation andRisk Evaluation","year":"2019","journal-title":"Strategies | REMS"},{"key":"10.1016\/j.contraception.2021.03.031_bib0012","article-title":"Asked Questions (FAQs) about","author":"Center for Drug Evaluation and Frequently","year":"2018","journal-title":"REMS"},{"key":"10.1016\/j.contraception.2021.03.031_bib0013","unstructured":"U.S. Food & Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS) n.d. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm."},{"key":"10.1016\/j.contraception.2021.03.031_bib0014","article-title":"FDA\u2019s Application of Statutory Factors in Determining When a REMS Is Necessary","author":"Center for Drug Evaluation andREMS","year":"2019","journal-title":"FDA"},{"key":"10.1016\/j.contraception.2021.03.031_bib0015","article-title":"What\u2019s in a REMS?","author":"Center for Drug Evaluation and","year":"2018","journal-title":"FDA"},{"key":"10.1016\/j.contraception.2021.03.031_bib0016","unstructured":"Risk Evaluation and Mitigation Strategy (REMS) Single Shared System for Mifepristone 200mg 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/rems\/Mifepristone_2019_04_11_REMS_Full.pdf."},{"key":"10.1016\/j.contraception.2021.03.031_bib0017","unstructured":"Center for Drug Evaluation and Application Number Research. REMS. 020687Orig1s020 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/020687Orig1s020RemsR.pdf"},{"key":"10.1016\/j.contraception.2021.03.031_bib0018","unstructured":"World Health Organization. Safe abortion: technical and policy guidance for health systems (2nd ed.) 2012."},{"key":"10.1016\/j.contraception.2021.03.031_bib0019","unstructured":"Letter from Woodcock J. RE: NDA 020687 Supp 20 2016, included as part of CDER Risk Assessment and Risk Mitigation Review(s) for Application Number 020687Orig1s020, (2016). Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/020687Orig1s020RiskR.pdf."},{"key":"10.1016\/j.contraception.2021.03.031_bib0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMsb1612526","article-title":"Sixteen years of overregulation: time to unburden mifeprex","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2021.03.031_bib0021","article-title":"Position statement: improving access to mifepristone for reproductive health","year":"2018","journal-title":"indications"},{"key":"10.1016\/j.contraception.2021.03.031_bib0022","article-title":"Ending the risk evaluation and mitigation strategy (REMS) policy on mifepristone","author":"American Medical Resolution 504","year":"2018","journal-title":"(Mifeprex)"},{"key":"10.1016\/j.contraception.2021.03.031_bib0023","article-title":"American Academy of Family Physicians","year":"2018","journal-title":"Resolution No. 506 (Co-Sponsored C), Removing REMS Categorization on Mifepristone"},{"key":"10.1016\/j.contraception.2021.03.031_bib0024","volume":"20","author":"Michael Munger","year":"2019","journal-title":"American Academy of Family Physicians. Letter to Acting Commissioner Sharpless"},{"key":"10.1016\/j.contraception.2021.03.031_bib0025","unstructured":"Chelius v. Wright, D. Haw. No. 1:17-cv-00493 (2017)."},{"key":"10.1016\/j.contraception.2021.03.031_bib0026","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMp1908305","article-title":"Time to reevaluate U.S. mifepristone restrictions","volume":"381","author":"Henney","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2021.03.031_bib0027","article-title":"Medical review: Application Number: 202107Orig1s000","author":"Zemskova","year":"2012","journal-title":"Center for Drug Evaluation and Research"},{"key":"10.1016\/j.contraception.2021.03.031_bib0028","unstructured":"Center for Drug Evaluation and Research, Medical Review, Application Number: 20-687. 2000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/20687_Mifepristone_medr_P1.pdf."},{"key":"10.1016\/j.contraception.2021.03.031_bib0029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/AOG.0000000000000897","article-title":"Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review","volume":"126","author":"Chen","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2021.03.031_bib0030","series-title":"Risk Assessment and Risk Mitigation Review: Application Number: 202107Orig1s000","author":"Robottom","year":"2012"},{"key":"10.1016\/j.contraception.2021.03.031_bib0031","doi-asserted-by":"crossref","unstructured":"Koonin L.M., Hoots B., Tsang C.A., Leroy Z., Farris K., Jolly B.T., Trends in the Use of Telehealth During the Emergence of the COVID-19 Pandemic \u2014 United States, January\u2013March 2020. MMWR Morb Mortal Wkly Rep 2020;69:1595-9. https:\/\/doi.org\/10.15585\/mmwr.mm6943a3.","DOI":"10.15585\/mmwr.mm6943a3"},{"key":"10.1016\/j.contraception.2021.03.031_bib0032","unstructured":"American College of Obstetricians & Gynecologists, v. United States Food and Drug Administration et\u00a0al., No. 8:20-cv-01320 (D. Md. May 27, 2020)."},{"key":"10.1016\/j.contraception.2021.03.031_bib0033","unstructured":"DeGette D., Lee B., Schakowsky J., Pressley A. 20 years later, the FDA must lift restrictions on medication abortion care. The Hill (2020). https:\/\/thehill.com\/blogs\/congress-blog\/healthcare\/518609-20-years-later-the-fda-must-lift-restrictions-on-medication."},{"key":"10.1016\/j.contraception.2021.03.031_bib0034","article-title":"Letter to Secretary Azar and Commissioner Hahn","author":"Becerra","year":"2020","journal-title":"State of California Office of the Attorney General;"},{"key":"10.1016\/j.contraception.2021.03.031_bib0035","unstructured":"Abortion Care Network, et al. Re: Request Regarding COVID-19, Docket: FDA-2020-D-1106. April 28, 2020. https:\/\/downloads.regulations.gov\/FDA-2020-D-1106-0100\/attachment_1.pdf."},{"key":"10.1016\/j.contraception.2021.03.031_bib0036","unstructured":"Ted Cruz, Letter to FDA Commissioner Hahn, September 1, 2020, available at https:\/\/www.cruz.senate.gov\/files\/documents\/Letters\/2020.09.01%20\u2013%20Pro-Life%20Mifeprex%20Letter%20to%20FDA%20-%20FSV.pdf."}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782421001037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782421001037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:19:19Z","timestamp":1757881159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782421001037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0010782421001037"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2021.03.031","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abortion exceptionalism and the mifepristone REMS","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2021.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}